ArticleAmerican journal of cancer research2025
Impact of immediate intravesical therapy on non-muscle invasive bladder cancer with risk factors analysis for recurrence.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of immediate intravesical therapy (IIT) on recurrence rates in non-muscle invasive bladder cancer (NMIBC) patients and to explore the potential protective role of vitamin supplementation.
methodsA retrospective analysis was conducted on 216 NMIBC patients treated between April 2019 and March 2023. Patients were categorized into two groups: IIT group (n = 154) and no-IIT group (n = 62). Inclusion criteria included pathologically confirmed NMIBC, initial transurethral resection of bladder tumor (TURBT), and a minimum follow-up of one year. Patients who underwent radical cystectomy, had other malignancies, or suffered from severe comorbid conditions were excluded. Recurrence within one year post-treatment was used to stratify patients into recurrence and non-recurrence groups. Statistical analyses were performed to identify factors significantly associated with recurrence. Logistic regression and receiver operating characteristic curve analyses were employed to evaluate predictive performance.
resultsThe recurrence rate was significantly lower in the IIT group (33.12%) compared to the no-IIT group (95.16%, P < 0.001). IIT significantly reduced the risk of recurrence (P < 0.001). Among vitamin supplements, only vitamin K3 demonstrated a significant association with recurrence (P = 0.010). Logistic regression confirmed IIT as an independent protective factor (OR = 0.026, P < 0.001). The area under the curve (AUC) for individual predictors ranged from 0.587 to 0.754, while the combined model achieved an AUC of 0.877, indicating strong predictive performance.
conclusionIIT and self-supplementation with vitamin K3 are associated with a reduced risk of NMIBC recurrence. These findings suggest that adjunctive strategies alongside standard transurethral resection of bladder tumor may enhance patient outcomes. Further prospective studies are warranted to confirm these associations and support their integration into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.